NASDAQ · TTRX

Turn Therapeutics Inc.

$8.54 -$0.94 (-9.92%) 1D After hours

Key Metrics

$282.39M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.37
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 7
    The stock moved +26.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 7
  • Jun 1
    The stock moved +21.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 1
  • Apr 1
    From its Jan 29 high, the share price fell 28%.

    Peak close $4.35 on Jan 29; trough close $3.12 on Apr 1. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$282.39M
Enterprise value$277.32M
Shares outstanding29.8M
52-wk range$2.57 – $26.50
Avg volume · 20D175.5K
Net cash $5.07M
Book value / share$0.21
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Turn Therapeutics Inc.
IPO dateOct 8, 2025
Employees2

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio2.23
Quick ratio
Debt / equity0.97
Debt / EBITDA
Net cash $5.07M
Working capital$6.32M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings